// App-Quantinova.ai

1504 : Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years

Researchers

Presenter

  • Corinne Miceli-Richard

Principal Investigators

  • Sonja Gill

  • Marina Magrey

  • Paula Machado

  • Abhijit Shete

  • Jianyuan Wang

  • Susanne Rohrer

  • Atul Deodhar

Medical Centers

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom

  • Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France

  • 412 – 3075 Hospital Gate, Oakville, Canada

  • Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Oregon Health and Science University, Portland, OR

Locations

  • United Kingdom

  • France

  • Canada

  • United States

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved